TY - JOUR
T1 - Treatment of uterine leiomyomas with luteinizing hormone-releasing hormone antagonist Cetrorelix
AU - Gonzalez-Barcena, David
AU - Alvarez, Raquel Bañuelos
AU - Ochoa, Elizabeth Pere
AU - Cornejo, Imelda Cardenas
AU - Comaru-Schally, Ana M.
AU - Schally, Andrew S.
AU - Engel, Juergen
AU - Reissmann, Thomas
AU - Riethmüller-Winzen, Hilde
N1 - Copyright:
Copyright 2018 Elsevier B.V., All rights reserved.
PY - 1997
Y1 - 1997
N2 - The efficacy of the luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) in the medical management of uterine leiomyomas (fibromas) was evaluated. Cetrorelix was administered to 18 pre-menopausal women with myomas with a mean age of 33.3 years, who had been candidates for hysterectomy. The initial dose of Cetrorelix was 5 mg twice daily s.c. for the first 2 days and thereafter 0.8 mg was given twice daily s.c. for at least 3 months. The mean duration of the treatment was 4.4 months. Before the therapy with Cetrorelix, the mean uterine volume, measured by ultrasonography, was 395.4 ± 69.2 ml (range 89-1166). Sixteen patients showed a progressive reduction in uterine volume from 410.4 ± 77.1 to a mean of 230.8 ± 52.6 ml at 3 months. All patients became amenorrhoeic and had hot flushes. After treatment with Cetrorelix, a surgical myomectomy was performed in 12 women. One of the patients subjected to myomectomy after therapy with Cetrorelix became pregnant. These patients have been followed for up to 25 months and only in one case has the uterine volume increased after therapy. Three patients had good responses to therapy with Cetrorelix and it was decided to follow them only by observation. One patient became pregnant 2 months later. In the other patient, the uterine volume remained unchanged for the duration of the follow-up of 2 years and the third patient showed an increase after 21 months. In three patients, it was necessary to perform total hysterectomy. In 14 patients, serum concentrations of luteinizing hormone, follicle stimulating hormone and oestradiol decreased after the administration of the first dose of Cetrorelix and continued at subnormal values throughout therapy. In 15 patients who were not subjected to total hysterectomy, menstrual function returned at 1 month after cessation of treatment. Overall results support the use of Cetrorelix for the management of uterine leiomyomas.
AB - The efficacy of the luteinizing hormone-releasing hormone antagonist Cetrorelix (SB-75) in the medical management of uterine leiomyomas (fibromas) was evaluated. Cetrorelix was administered to 18 pre-menopausal women with myomas with a mean age of 33.3 years, who had been candidates for hysterectomy. The initial dose of Cetrorelix was 5 mg twice daily s.c. for the first 2 days and thereafter 0.8 mg was given twice daily s.c. for at least 3 months. The mean duration of the treatment was 4.4 months. Before the therapy with Cetrorelix, the mean uterine volume, measured by ultrasonography, was 395.4 ± 69.2 ml (range 89-1166). Sixteen patients showed a progressive reduction in uterine volume from 410.4 ± 77.1 to a mean of 230.8 ± 52.6 ml at 3 months. All patients became amenorrhoeic and had hot flushes. After treatment with Cetrorelix, a surgical myomectomy was performed in 12 women. One of the patients subjected to myomectomy after therapy with Cetrorelix became pregnant. These patients have been followed for up to 25 months and only in one case has the uterine volume increased after therapy. Three patients had good responses to therapy with Cetrorelix and it was decided to follow them only by observation. One patient became pregnant 2 months later. In the other patient, the uterine volume remained unchanged for the duration of the follow-up of 2 years and the third patient showed an increase after 21 months. In three patients, it was necessary to perform total hysterectomy. In 14 patients, serum concentrations of luteinizing hormone, follicle stimulating hormone and oestradiol decreased after the administration of the first dose of Cetrorelix and continued at subnormal values throughout therapy. In 15 patients who were not subjected to total hysterectomy, menstrual function returned at 1 month after cessation of treatment. Overall results support the use of Cetrorelix for the management of uterine leiomyomas.
KW - Cetrorelix
KW - Hysterectomy
KW - LH-RH antagonist
KW - Uterine leiomyomas
UR - http://www.scopus.com/inward/record.url?scp=0030730449&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030730449&partnerID=8YFLogxK
U2 - 10.1093/humrep/12.9.2028
DO - 10.1093/humrep/12.9.2028
M3 - Article
C2 - 9363724
AN - SCOPUS:0030730449
VL - 12
SP - 2028
EP - 2035
JO - Human Reproduction
JF - Human Reproduction
SN - 0268-1161
IS - 9
ER -